Iantum Technologies Ltd Unlocking atomic energy for human regeneration

CEO & Founder Dr Keryn Johnson PhD MSc BSc – Founded on 18/03/2019

Company Purpose

Putting the power of healing into people's hands


The Pain 50 million people with Bipolar disorder.

No known mechanism and no known cure

The global **bipolar** disorder **market** is anticipated to reach USD 4.9 billion by 2025, growing at a CAGR of 2.10%

A market ready Solution

Patent protected - apitherapy light healing technology





OH BEE HAVE


The mechanism of bipolar has now been discovered. A topical solution containing mono-atomics has been developed and shown to help heal the mind

A new science based on single atom physics has been developed to explain monoatomic function in the unconscious mind. Unlocking time.





Formulated into a topical spray that is bioavailable for supporting the physics of the unconscious mind.






Containing a biophoton generating system for cognitive enhancement and regeneration that supports longevity





lens


Our retina point inwards The mind creates the light we see and the mechanism responsible for the atomic light show is now understood.




pupil

iris


AWARDS SEEING INTO THE






WHAT IS THE CORRECT FOCAL POINT FOR THE LENS?

An isotope singularity physics model for memory formation and recall has been developed by Quantum **Technologies Ltd** identifies the location of quantum tunnelling within neurotransmitters




The light within the mind is released through atomic decay of isotopes created through hydrogen tunnelling into single atoms housed in the aromatic ring of neurotransmitters





Time and its directional flow is based on isotope physics decay processes going from high energy to low energy

Quantum Technologies Ltd has unlocked time in biology to experience the restoration of memory and spiritual healing connected to the atomic singularity within Lyman vision of a golden sphere of light (atomic nucleus) Opening the ring structure of neurotransmitters releases the atomic memory stored in the electromagnetic field

This results in the release of trauma and facilitates healing from past trauma








Unlocking light within atoms to restore memory and health in a range of diseases of the mind.


Several clinical case studies showing the benefits of the topical royal jelly spray manufactured from Manuka



First mover advantage

IP Clinical effectiveness demonstrated in clinical case studies New science platform for restoring memory and unlocking time reversal symmetry in atomic decay processes

From: Architecture of the native major royal jelly protein 1 oligomer



Customer Feedback






• Mum says "something is slowing down or stopping my arthritis". I've had her on two sprays a day, one for each hand for a couple of months. Yeah, and her eyes are so clear & she's mentally sharper. Thanks! I have also been using it and definitely more energy & more connected & less reactive too.

• It helped heal my PTSD. A real benefit for me in starting my new role at work. Thanks.

• I gave a bottle of the headache, muscle and joint spray to my 91-year-old mother who has had chronic neck pain. She felt instant relief. She is applying it daily and said that her neck movement is increasing daily. Betty Bryson

<u>https://youtu.be/tIHCYicKX_Y</u>



Business model

IP capture and licensing of MEL-RJPI for cosmetic applications to support clinical development of therapeutic indications in brain health applications

Initial licensing activity (non-exclusive) 15% royalty stream


Global opportunities are massive

Market feedback

- 2020 \$1147
- 2021 \$4652
- 2022 \$23707
- 2023* \$100K
- 2024* \$500K
- 2025* \$2.5M

Latest sale \$6,250.00 with a distribution deal into Indonesia to test the market 1080 x 100mL bottles B2B not B2C

Licensing royalties *Growth 500



Competition


Proton therapy

Nootropic oral products

Pharmaceutical interventions e.g. Li+

Biophoton mediated therapies

Med beds and plasma devices



Competitive advantage

COGS

Natural (shift away from Pharma approaches)

Historical use of honey

Multiple licensing opportunities to generate revenue streams

Intellectual property

IP for product manufacture

IP for HDAC inhibition and industrial application in various indications

Brands and Trade secrets

Pipeline of clinical opportunities

 (12) INTERNATIONAL APPLICATION PUBLISHED ((19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 February 2022 (17.02.2022) WIPO F 		UNDER THE PATENT COOPERATION TREATY (PCT)
International Patent Classi A61K 35/644 (2015.01) A61P 9/00 (2006.01) A61P 25/00 (2006.01)	A61P 31/12 (2006.01) A61P 35/00 (2006.01) A61P 37/00 (2006.01)	MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
A61P 25/18 (2006.01)		Published:
A61P 23/28 (2006.01) A61P 29/00 (2006.01) A61P 31/00 (2006.01) A61P 31/04 (2006.01)	B01D 15/36 (2006.01) B01J 47/014 (2017.01) G01N 33/15 (2006.01)	 with international search report (Art. 21(3)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
(21) International Application Number:		
International Filing Date:	PCT/NZ2021/050128	
Filing Language:	English	
Publication Language:	English	
Priority Data: 767031 11 Aug	gust 2020 (11.08.2020) NZ	
(71) Applicant: QUANTUM TECHNOLOGIES LIMITED [NZ/NZ]; 39A Bombay Street Ngaio, Wellington, 6035 (NZ).		
Inventor: JOHNSON, Kery Wellington, 6035 (NZ).	yn; 39A Bombay Street Ngaio,	
Agent: NOWAK, David; Wellington, 6011 (NZ).	Level 7, 158 Victoria Street,	
kind of national protection of AO, AT, AU, AZ, BA, BB, E CA, CH, CL, CN, CO, CR, C DZ, EC, EE, EG, ES, FI, GE HR, HU, ID, IL, IN, IR, IS,	available): AE, AG, AL, AM, BG, BH, BN, BR, BW, BY, BZ, CU, CZ, DE, DJ, DK, DM, DO, B, GD, GE, GH, GM, GT, HN, IT, JO, JP, KE, KG, KH, KN,	
	A61K 35/644 (2015.01) A61P 9/00 (2006.01) A61P 25/00 (2006.01) A61P 25/18 (2006.01) A61P 25/28 (2006.01) A61P 25/28 (2006.01) A61P 25/28 (2006.01) A61P 31/00 (2006.01) A61P 31/04 (2006.01) International Application I Filing Language: Priority Data: 767031 11 Aug Applicant: QUANTUM TF [NZ/NZ]; 39A Bombay Str (NZ). Inventor: JOHNSON, Kerg Wellington, 6035 (NZ). Agent: NOWAK, David; 1 Wellington, 6011 (NZ). Designated States (unless of kin	A61P 9/00 (2006.01) A61P 35/00 (2006.01) A61P 25/00 (2006.01) A61P 37/00 (2006.01) A61P 25/18 (2006.01) A61P 43/00 (2006.01) A61P 25/28 (2006.01) B01D 15/36 (2006.01) A61P 29/00 (2006.01) B01J 47/014 (2017.01) A61P 31/00 (2006.01) G01N 33/15 (2006.01) A61P 31/04 (2006.01) G01N 33/15 (2006.01) International Application Number: PCT/NZ2021/050128 Filing Language: English Publication Language: English Priority Data: 767031 11 August 2020 (11.08.2020) NZ Applicant: QUANTUM TECHNOLOGIES LIMITED NZ/NZ]; 39A

CAM - Complementary medicine technology



Medical technology that restores memory function and enhances cognition (nootropic properties)

Clinical findings in early onset dementia, PTSD, bipolar and depression plus other indications

Clinical evaluation of memory restoration through a clinical case study in conjunction with the Brain Health Clinic in Christchurch, New Zealand.

Functional improvements observed in patients using the product topically daily.





Manufactured

under non-GMP and exported to Indonesia to test the market. If the market feedback is positive, then Company X is committed to invest capital for setting up a cGMP manufacturing facility in NZ for international export

Distribution agreement (non-exclusive) with company Y for international markets **Regulatory pathways** natural complementary medicine (CAM)

Cosmetic product INCI: MEL-RJPI Medical device: WAND

registration in NZ for wound care applications. Regulatory submission underway

Data pack for submission - Stability 2-year data (7 Dec 2022) Founder & CEO Dr Keryn Johnson quantum biologist and regenerative medicine expert

28 years scientific expertise Outcome driven solutions Proven track record with product solutions in over 4 million patients Aroa Biosurgery IP development



Team



Raw material supply Manuka honey producer Stu Ferguson

Clinical development Dementia patient liaison Janine McKenzie-Minifie



IP – Henry Huges – national phase filing

PCT International Application No. PCT/NZ2021/050128

<u>Manufacture</u> Quantum Technologies Ltd Dr Keryn Johnson CEO & Founder




Seed investment \$1.5M

Building out the Team

CTO, CFO, laboratory, manufacturing, regulatory and clinical development

Quentum Technologies 1050



For additional information please contact Dr Keryr Johnson <u>k.johnson@ohbeehave007.com</u> +64 221998782